Demolishing the Great Wall of Biofilms in Gram-negative Bacteria: To disrupt or disperse?

Running title: Biofilm dispersal and disruption

Author and Affiliations:

Miao Yu [1, 2], Song Lin Chua [1, 2 #]

1. Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR China
2. State Key Laboratory of Chemical Biology and Drug Discovery, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR China

Corresponding author:
Song Lin Chua
song-lin.chua@polyu.edu.hk

Acknowledgment:

This research is supported by The Hong Kong Polytechnic University, Department of Applied Biology and Chemical Technology Startup Grant (BE2B), and State Key Laboratory of Chemical Biology and Drug Discovery Fund (1-BBX8).

Competing interests:

The author declares no competing financial interests.

This is the peer reviewed version of the following article: Yu, M, Lin Chua, S. Demolishing the great wall of biofilms in Gram-negative bacteria: To disrupt or disperse? Med Res Rev. 2020; 40: 1103– 1116, which has been published in final form at https://dx.doi.org/10.1002/med.21647. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced,

Abstract:

Bacterial infections lead to high morbidity and mortality globally. While current therapies against bacteria often employ antibiotics, most bacterial pathogens can form biofilms and prevent effective treatment of infections. Biofilm cells can aggregate and encased themselves in a self-secreted protective exopolymeric matrix, to reduce the penetration by antibiotics. Biofilm formation is mediated by c-di-GMP signaling, the ubiquitous secondary messenger in bacteria. Synthesis of c-di-GMP by diguanylate cyclases (DGCs) leads to biofilm formation via the loss of motility, increased surface attachment, and production of biofilm matrix, whereas c-di-GMP degradation by phosphodiesterases (PDEs) causes biofilm dispersal to new sites via increased bacterial motility and matrix breakdown. The highly variable nature of biofilm development and antimicrobial tolerance imposes tremendous challenges in conventional antimicrobial therapies, indicating an imperative need to develop anti-biofilm drugs against biofilm infections. In this review, we focus on two main emergent approaches - active dispersal and disruption. While both approaches aim to demolish biofilms, we will discuss their fundamental differences and associated methods. Active dispersal of biofilms involves signaling the bacterial cells to leave the biofilm, where resident cells ditch their sessile lifestyle, gain motility and self-degrade their matrix. Biofilm disruption leads to direct matrix degradation that forcibly releases embedded biofilm cells. Without the protection of biofilm matrix, released bacterial cells are highly exposed to antimicrobials, leading to their eradication in biofilm infections. Understanding the advantages and disadvantages of both approaches will allow optimized utility with antimicrobials in clinical settings.

Keywords: Biofilms; dispersal; disruption; antimicrobial treatment; chronic infections

49 **Main Text:**

50 **1. Introduction**

51

52 1.1 Biofilm-mediated infections

53 Modern medicine has effectively eliminated acute infections caused by pathogenic bacteria and
54 prevented the deaths of millions over the past century. Yet, such diseases are increasingly
55 replaced by chronic infections caused by biofilms, which now accounts for 80% of all bacterial
56 infections [1]. Biofilms are bacterial communities growing in their slimy exopolymeric matrix, after
57 colonizing any biotic or abiotic surface. They colonize most surfaces in the human body and
58 medical devices, causing persistent infections such as chronic wound infections, endocarditis,
59 keratitis, and lung infections to implant-associated infections [2]. One biofilm-forming pathogen is
60 *Pseudomonas aeruginosa*, an opportunistic Gram-negative pathogen that causes 90,000
61 deaths annually [3] by causing life-threatening infections in burn wounds and pneumonia [4,5].

62

63 1.2 Clinical approaches to develop anti-biofilm therapies

64 While most research into antimicrobials focuses on the treatment of acute infections caused by
65 free-swimming planktonic bacteria, few commercial anti-biofilm drugs are available. Most anti-
66 biofilm treatments currently employed by clinicians are mostly based on aggressive early
67 surgical removal and delivery of sustained antimicrobial chemotherapy. Combinatorial
68 antimicrobial treatment such as colistin or tobramycin inhalations with oral ciprofloxacin are
69 frequently used to treat *P. aeruginosa* biofilm infections in cystic fibrosis lungs [6]. However,
70 treatment at higher antibiotic doses for sustained treatment periods, such as 3 million units of
71 colistin administered three times per day may pose health risks to patients [7]. Furthermore,
72 antibiotic resistance via efflux pumps, acquired resistance plasmids, or phenazine metabolites in
73 bacteria has significantly reduced treatment efficacy [8-10]. Hence, the discovery of novel anti-
74 biofilm drugs with lower toxicities and suitability for combinatorial use with antibiotics can
75 potentially eradicate biofilm infections, minimize treatment duration, and lower mortality rates.

76

77 Here, we summarize, assess, and compare anti-biofilm compounds that can disperse or disrupt
78 biofilms. Firstly, we provide background on biofilm physiology and its role in chronic infections.
79 Next, we analyze the anti-biofilm strategies adopted by biofilm dispersal and disruption agents.
80 Finally, we discuss the future directions of anti-biofilm therapies based on both approaches.

81

82

83 **2. Biofilm physiology and its roles in infections**

84

85 Briefly, the life cycle of bacterial biofilms involves planktonic cells attaching to a surface and
86 producing an exopolymeric matrix for biofilm growth and formation, with the mature biofilm
87 eventually dispersing to new sites of infection (Figure 1). Unlike 'nomadic' free-swimming
88 planktonic bacteria, biofilm cells survive as 'city-like' multicellular communities in self-produced
89 exopolymeric matrix (EPS). The EPS comprises exopolysaccharides, adhesion proteins, and
90 extracellular DNA (eDNA), primarily providing structural integrity to biofilms [11].

91

92 In chronic infections, biofilms can easily attach onto human tissues and extracellular matrix,
93 where dead cells and blood supply contribute to nutrient availability for biofilm growth [12].
94 Furthermore, the EPS acts as a protective barrier to reduce antimicrobial penetration, whereas
95 dormant persisters render biofilms extremely tolerant of antimicrobials [13,14]. These confounding
96 factors may lead to inaccurate results in antibiotic susceptibility tests, which are typically
97 performed on planktonic bacteria in clinical bacteriology, leading to inappropriate clinical doses
98 and incomplete eradication of infections [15]. The exopolymeric matrix protects biofilm cells from
99 phagocytosis and assists in immune evasion against the host immune system [16].

100

101 Understanding the mechanisms driving the biofilm life cycle can provide hints for the
102 development of novel anti-biofilm approaches [17]. Currently, two primary bacterial mechanisms
103 are extensively studied - quorum sensing (QS) and c-di-GMP secondary messenger system.
104 QS allows planktonic cells to coordinate their behavior in forming biofilms via surface
105 attachment, exopolymer production, and biosurfactant (rhamnolipids) synthesis [18,19]. QS
106 operated in a cell density-dependent manner – bacterial populations will coordinate their gene
107 expression once the autoinducers accumulated past a concentration threshold [20]. Coordinating
108 bacterial populations in biofilm dispersal also requires QS [21], where *P. aeruginosa* biofilms
109 secrete QS- controlled rhamnolipids as biosurfactants for detachment during dispersal [22].

110

111 The biofilm life cycle is mediated by c-di-GMP, an intracellular secondary messenger employed
112 by many Gram-negative bacterial species [23]. Synthesis of c-di-GMP levels within bacterial cells
113 by diguanylate cyclases (DGCs) often leads to biofilm formation via surface attachment,
114 reduced motility, and production of the exopolymeric matrix. Degradation of c-di-GMP by
115 phosphodiesterases (PDEs) to levels lower than that in planktonic cells will lead to biofilm
116 dispersal and increased flagellar motility [23] (Figure 2). Clinical isolates from various bacterial

117 species, such as the rough and small colony variants (RSCVs) of *P. aeruginosa* and
118 enteroaggregative *Escherichia coli*, possess constitutively high intracellular c-di-GMP levels
119 [24,25].
120
121 While our review focuses on both QS and c-di-GMP signaling, there are other mechanisms
122 mediating biofilm life cycle, such as the two-component system (TCS) [26] and iron siderophore
123 (pyoverdine) signaling [27], which contributes to further complexity in biofilm physiology. One
124 prominent example is the GacA/GacS TCS involved with pyoverdine synthesis and interaction
125 with c-di-GMP signaling [28]. Hence, the difficulty of treating biofilm infections is attributed to
126 complex and unique biofilm physiology, which warrants an urgent need to develop innovative
127 anti-biofilm approaches and drugs against biofilm infections.
128
129
130 **3. Development of anti-biofilm chemotherapy:**
131
132 To effectively eradicate biofilms, many anti-biofilm approaches have been developed, mainly
133 mechanical removal of biofilms, which includes electricity and sonication [29,30], and
134 chemotherapy, which is the focus of this review. Novel drug candidates must be developed for
135 effective anti-biofilm therapy of chronic infections in humans.
136
137 Current discovery of anti-biofilm compounds requires either high-throughput screening (HTS) or
138 systems biology approaches. Being focused on a specific target, HTS is usually achieved via *in*
139 *vitro* screening of compound libraries, such as the identification of biofilm-inhibiting patulin from
140 thousands of natural extracts [31]. The *in-silico* structure-based virtual screening is also an
141 alternative that employs molecular docking to identify which molecule from the compound
142 libraries can bind and inhibit a biofilm effector. For instance, emodin identified from traditional
143 Chinese medicine extracts could inhibit QS-mediated TraR in *E. coli* [32].
144
145 Systems biology approaches are employed in various ways to facilitate the discovery of
146 compounds with novel or multiple mechanisms of action. Conventionally, we identify potential
147 mechanisms of action by comparing the transcriptomic or proteomic signatures of wild-type and
148 deletion mutants [33] or treated with an unknown chemical and antibiotics with known mechanism
149 of action [34]. Undirected approaches with large compound libraries are gaining traction in anti-
150 biofilm discovery. For instance, functional metagenomics from seawater samples are employed

to identify anti-biofilm compounds against *Vibrio cholerae* and *P. aeruginosa* [35,36], while transcriptomics and proteomics are used to study the anti-biofilm activity of 3-Furancarboxaldehyde On Group A Streptococcus [37].

Anti-biofilm chemotherapy can be achieved via a variety of approaches: inhibition of bacterial attachment to surfaces and biofilm formation, active dispersal of biofilms, and disruption of biofilm matrix (Figure 2). Since most biofilms are already established in chronic infections which rendered inhibitors of biofilm formation unsuitable, this review will focus on active dispersal and disruption of biofilms. Although both approaches are previously grouped as 'active dispersal,' we will differentiate them in this review for clarity.

Active dispersal and disruption seemingly have the same objective – to ensure the dissolution of EPS and release of biofilm cells, which presumably return to the planktonic phase. As released bacterial cells are wholly exposed to antimicrobials, combining either approach with antibiotics will eradicate biofilms and prevent freed pathogens from causing disseminated infections. However, both methods are fundamentally different (Figure 3). Active dispersal involves a chemical stimulus that signals bacterial cells to terminate their biofilm lifestyle and exit the EPS via the self-production of matrix-degrading enzymes and expression of motility apparatus (flagella or pili). Biofilm disruption is the direct targeting or degradation of biofilm matrix, leading to the catastrophic collapse of biofilm structure and ejection of embedded cells. It is crucial to understand their differences so that we can take advantage of their strengths and reduce their limitations for treating biofilm infections.

3.1 Inducing biofilm dispersal

While biofilm dispersal is a highly regulated natural process, we can manipulate biofilm cells into leaving their protective 'wall' of EPS by providing a specific stress stimulus and allowing antibiotics to eradicate freshly dispersed cells (Figure 4A). Active biofilm dispersal can be achieved via three approaches: QS targeting agents, DGC inhibitors, and PDE activators (Figure 4A).

3.1.1 QS-targeting agents

Exogenous QS signaling molecules or associated products are reported to induce biofilm dispersal. Although QS autoinducers can induce biofilm formation in native bacterial species, they can also act as chemorepellants. For instance, exogenous AI-2 autoinducer could induce

185 *Helicobacter pylori* biofilm dispersal [38], while AIP-1 could reduce *S. aureus* biofilms after 48 hrs
186 [39]. Interestingly, N-(3-oxo-dodecanoyl) homoserine lactone from *P. aeruginosa* could cause
187 biofilm dispersal in a foreign species, *Escherichia coli* [40]. Diffusible signal factor (DSF), a fatty-
188 acid-based QS system found in *P. aeruginosa*, *Burkholderia,* and *Xanthomonas* species, was a
189 cross-kingdom signaling molecule which caused biofilm dispersal in prokaryotic and yeast
190 species when added exogenously [41,42].
191
192 QS-mediated products can also induce biofilm dispersal. QS-mediated rhamnolipids from *P.*
193 *aeruginosa* acted as biosurfactants that disperse biofilms of other species [40,43]. Moreover,
194 surfactin secreted from *Bacillus subtilis* could disperse biofilms from food-borne pathogens such
195 as *Listeria monocytogenes* and *Salmonella enterica*, grown on polystyrene material [44]. While
196 promising in dispersing biofilms, such biosurfactants are cytotoxic to host cells [45], which can
197 limit their applications in clinical settings.
198
199 3.1.2 DGC inhibitors
200 Inhibition of c-di-GMP signaling is an attractive approach to target various pathogenic biofilms.
201 DGC inhibitors identified from high-throughput screening could reduce c-di-GMP levels and
202 decrease biofilm formation [46]. Terrein could inhibit both QS and DGC, effectively reducing
203 virulence and biofilm formation in *P. aeruginosa,* respectively [47]. C-di-GMP analogs, such as
204 triazole-linked analogs, could compete with c-di-GMP for active sites in DGCs, to disrupt c-di-
205 GMP signaling [48]. However, it is essential to note that such inhibitors must penetrate biofilm
206 matrix to reach bacterial cells. Thus poor permeability of these compounds may significantly
207 limit their therapeutic purposes in established chronic infections. The permeability issue should
208 be addressed by either using nanoparticles or utility in thin nascent biofilms.
209
210 3.1.3 PDE activators
211 PDE activators can induce biofilm dispersal via c-di-GMP degradation *in vitro* and *in vivo* [49,50].
212 Most notably, nitric oxide (NO) could induce dispersal in many bacterial species at sub-lethal
213 concentrations [51], by binding NO-sensing H-NOX-domain protein [52] and activating PDEs (DipA
214 and NbdA in *P. aeruginosa*) that degrade c-di-GMP [49,53]. Given the DGCs/PDEs redundancy in
215 each bacterial species, it is essential to note that not all PDEs control biofilm dispersal. Instead,
216 PDEs such as RocR controlled swarming and production of virulence factors [54]. Hence, it is
217 crucial to ensure that activators must correctly activate PDEs with known dispersal roles.
218

219 Despite its low cost and ease of administration via inhalers, using gaseous NO is clinically
220 challenging due to its poor stability, pleiotropic effects on the host body in systemic exposure
221 such as vasodilation, and lack of specificity against bacterial species. Various NO donors, such
222 as sodium nitroprusside [55], were identified with varying NO production and half-lives. To
223 improve the specificity of NO to biofilms, cephalosporin-3'-diazeniumdoilates, made of stable
224 NO donor diazeniumdiolate conjugated to cephalosporin, could deliver NO after being degraded
225 by biofilm-produced beta-lactamases, to eradicate *Haemophilus influenzae* biofilms [56].
226 Nitroxides, such as 4-carboxy-2,2,6,6-tetramethylpiperidine 1-oxyl (carboxy-TEMPO), 5-
227 carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl (CTMIO) and 5,6-dicarboxy-1,1,3,3-
228 tetraethylisoindolin-2-yloxyl (DCTEIO), which were sterically hindered NO mimetic analogues,
229 could disperse biofilms [57]. As such, nitroxides were utilized in combination with ciprofloxacin to
230 eradicate biofilm effectively [58].
231
232 Despite its aforementioned limitations, NO had been tested in clinical trials against biofilm
233 infections. Low-dose NO inhalation was tested in cystic fibrosis patients with pneumonia, with
234 markedly reduced biofilm size and improved patient outcomes [59]. A phase II clinical study is
235 currently in progress, where patients with cystic fibrosis will inhale 0.5% NO four times a day [60].
236 Hence, the prospect of using NO as a PDE activator remains promising in dispersing biofilms in
237 infections.
238
239 3.2 Disruption of the biofilm matrix
240 Although EPS composition varies across time, location, nutrient availability, mechanical or shear
241 stresses, and bacterial species, EPS functions are consistent – bacterial adherence, acting as a
242 scaffold for biofilms and barrier against host effectors or antimicrobials. To nullify EPS functions,
243 we will discuss three approaches that directly disrupt biofilm matrix: enzymatic and non-
244 enzymatic degradation of EPS components; and antibody targeting of exopolymeric matrix
245 (Figure 4B).
246
247 3.2.1 Enzymatic degradation of EPS components
248 Since the EPS contains mainly exopolysaccharides [61], matrix-degrading enzymes can degrade
249 EPS to release biofilm cells. The earliest report of glycosyl hydrolase, which hydrolyzed poly-
250 acetyl glucosamines in biofilms in various bacterial species, was Dispersin B, which was
251 produced by *Aggregatibacter actinomycetemcomitans* [62]. *P. aeruginosa* self-produced glycoside
252 hydrolases, such as PslG and PelA, were recently discovered to disrupt Psl and Pel

253 exopolysaccharides, thus improving antimicrobial treatment and immune clearance respectively
254 [63,64]. Alginate, another exopolysaccharide expressed by CF-derived mucoid *P. aeruginosa* and
255 coccoid *Helicobacter pylori*, was effectively disrupted by alginate lyase [65,66]. Further, α-amylase
256 and cellulase could disrupt *Staphylococcus aureus* and *Pseudomonas aeruginosa* polymicrobial
257 biofilms in wounds to some degree [67].
258
259 The DNase can also disrupt biofilms by degrading the eDNA integrated with other EPS
260 components for structural support [68]. Recombinant human DNase I (dornase alfa) was shown in
261 clinical trials to degrade microbial eDNA in the sputum of patients with cystic fibrosis [69] and
262 ventilator-associated infection in preterm infants [70].
263
264 Lastly, the degradation of adhesion and extracellular proteins by proteases can disrupt biofilms
265 efficiently. A plant protease, ficin, was recently discovered with the ability to disrupt
266 *Staphylococcus aureus* biofilms and release biofilm cells [71]. Serine proteases from other
267 bacterial species, such as *Bacillus pumilus*, were effective against *Serratia marcescens* biofilms
268 [72]. As proteases are commonly used as therapeutics in treating cardiovascular diseases, it is
269 highly probable that future clinical trials featuring anti-biofilm proteases will be conducted.
270
271 ### 3.2.2 Non-enzymatic degradation of EPS components
272 A few compounds that can cause EPS degradation had been identified. The FDA-approved N-
273 acetyl cysteine (NAC), whose mucolytic ability to dissociate disulfide bonds in extracellular
274 mucin proteins and reduce their viscosity, was subsequently expounded into a potential anti-
275 biofilm agent. NAC was employed in modern applications, such as combinatorial treatment with
276 cysteamine, an antioxidant against mixed biofilms of *Streptococcus pneumoniae* and
277 *Haemophilus influenzae* [73]. Another garlic-derived compound, Rafflinose, could inhibit biofilms
278 by binding to lectin-A, which is an exopolysaccharide-binding protein in *P. aeruginosa* [74].
279
280 An alternate non-enzymatic approach involves the use of biological hydrogels such as mucins to
281 trigger biofilm dispersal via the activation of flagella, promoting of native microbiota colonization,
282 and prevention of pathogen attachment [75]. One biopolymer currently tested in clinical trials is
283 SP1SN13, a poly-N-(acetyl, arginyl) glucosamine (PAAG) glycopolymer with anti-biofilm effects
284 on *P .aeruginosa* in cystic fibrosis patients [76]. After a successful Phase I determining safety and
285 tolerability in patients, SP1SN13 had received orphan designation by FDA and will undergo
286 Phase II clinical trial in late 2019.

287
288 3.2.3 Specific targeting of the exopolymeric matrix by antibodies
289 Another anti-biofilm approach is to employ antibodies specific against EPS components. For
290 instance, monoclonal antibodies specific against epitopes on *P. aeruginosa*-produced
291 exopolysaccharide Psl were developed to target biofilms formed by clinical isolates [77]. Since
292 secreted Psl is easily accessible by antibodies, the anti-Psl antibody was effective at promoting
293 opsonized phagocytic killing of *P. aeruginosa* biofilms and inhibiting the pathogen from adhering
294 to the cell surfaces. The bispecific antibody (MEDI3902) specific against both Type III Secretion
295 System and Psl was subsequently developed with a broad coverage against *P. aeruginosa* [78]. A
296 Phase I clinical trial with MDI3902 was reported recently with acceptable safety and tolerability
297 in healthy volunteers [79], paving the way for Phase II clinical trial.
298
299 Antibodies are also developed to target adhesion proteins. The integration host factor (IHF)
300 specifically targeted eDNA-binding proteins (DNABII) in biofilms in *Escherichia coli* biofilms [80]
301 and *Porphyromonas gingivalis* biofilms [81]. It is currently co-administered with recombinant type
302 IV pili, leading to the disruption of biofilms formed by *Haemophilus influenza* in otitis media [82].
303
304
305 **4. Comparison between biofilm dispersal and disruption in anti-biofilm treatments:**
306
307 Since both approaches are different from each other, it is critical to consider their strengths and
308 limitations to realize their full potential in eradicating biofilm infections (Table 1).
309
310 4.1 Strengths and limitations in active dispersal
311 Many biofilm dispersal agents, such as NO, are quick-acting chemicals. NO can be applied on a
312 wide range of microbial species, ranging from Gram-positive and Gram-negative bacteria to
313 yeast, thus it is useful in treating polymicrobial biofilm infections [51]. The use of low-dose and
314 non-bactericidal concentrations of NO or NO-deriving compounds can also induce biofilm
315 dispersal. Using pico-nanomolar NO concentrations for biofilm dispersal can prevent undesired
316 effects of high NO concentrations on the human body, such as vasodilation in blood vessels,
317 damage to host cells, inhibition of lymphocyte proliferation and delays in healing. Moreover,
318 elevated NO concentrations have a counterintuitive effect of protecting bacteria from antibiotics,
319 leading to poor antimicrobial effects [83].
320

321 Aside from chemical-specific side effects, there are other factors to consider when using biofilm
322 dispersal agents. Biofilm-dispersed cells possessed lower c-di-GMP levels than in planktonic
323 and biofilm cells of multiple species [49], which gave rise to a unique transient dispersal
324 phenotype with heightened expression of virulence factors [49,84,85]. Worse, biofilm-dispersed cells
325 possess different antibiotic resistance via different stimuli [86], such as increased resistance to
326 colistin in *P. aeruginosa* [87]. The increased resilience against immune and antimicrobial stresses
327 is probably because dispersed cells have to 'arm' themselves in advance for protection against
328 predators or chemical stimuli as they leave the biofilm's shelter [49]. Hence, caution may be
329 required when biofilm-dispersed cells are not entirely eradicated by antimicrobials, potentially
330 leading to complications where residual bacteria enter the bloodstream.
331
332 Lastly, the penetrability of drugs into biofilms remains a challenge to achieve in developing
333 dispersal agents. While NO has high penetrability into biofilms [51], other dispersal agents may
334 face difficulty in penetrating the biofilm matrix and reaching deeply embedded cells even if they
335 fulfill the Lipinski's Rule of Five. However, the high lability of NO can shorten its duration of
336 effective dose, so stable NO donors or sustained NO treatment are required to treat biofilm
337 effectively. Hence, we must consider these factors in the future design of biofilm dispersal
338 agents.
339
340 <u>4.2 Strengths and limitations of biofilm disruption</u>
341 There are several advantages of employing biofilm disruption of anti-biofilm strategy. Firstly,
342 biofilm disruption promotes the catastrophic collapse of the biofilm structure rapidly at low
343 concentrations, which is attributable to the highly efficient enzymatic activity of matrix-degrading
344 enzymes. For instance, nanomolar levels of PslG (IC_{50} = 10 nM) could disrupt Psl fibers within 4
345 minutes and disassemble *P. aeruginosa* biofilms in 30 minutes [63].
346
347 While active dispersal can induce physiological changes to biofilm and dispersed cells, it is
348 unclear if biofilm disruption has any immediate physiological effects on bacterial cells upon
349 sudden release from their bounds. However, studies had shown that *P. aeruginosa* cells
350 released from biofilms by PslG or EndA have similar antibiotic resistance to planktonic cells or
351 biofilms cells from which they originate [63,88], implying that bacterial cells did not have time to
352 adjust their physiologies significantly after sudden release from biofilms. These treatments are
353 advantageous as biofilm-disrupted cells remain susceptible to antimicrobial treatment, so
354 standard dosages of antimicrobials may be enough to eradicate both biofilm and disrupted cells.

Next, biofilm disruption can circumvent the need for penetration by biofilm disruptors into biofilms. Biofilm disruptors can demolish the biofilms from the outside at accelerated pace, without having to pass through the biofilm matrix and microbial cell walls. In contrast, depending on the chemical penetrability into biofilms, dispersal agents may require hours to days for active dispersal to occur [49,51].

The specificity of biofilm-disruptors is also an essential factor to be considered for anti-biofilm treatment. The matrix-degrading enzymes are in general specific to the species, but cross-reactivity is possible if the chemical composition of substrates is similar. For instance, PslG is specific to a few close-related species, such as *P. aeruginosa* and plant pathogen *Pseudomonas syringae*, but has no effect on *E. coli*, *S. aureus*, *S. enterica* and *Candida albicans* [63]. Yet, DNase applies to a broader multitude of bacterial species, as it does not distinguish eDNA produced by different bacterial species.

However, biofilm disruptors are not without limitations. Like most enzymes, matrix-degrading enzymes suffer from poor stability, susceptibility to host degradation, sensitivity to changes in temperature, and pH. Furthermore, complex pharmacodynamics and pharmacokinetics in hosts can compromise the efficacy of biofilm disrupting enzymes *in vivo*. Despite showing the viability and safety of using disrupting agents in animal studies [67], they can alert the host immune system if they originate from non-human species [89]. Lastly, previous concerns over expenses, low production yield and lack of genetically optimized enzymes contribute to the difficulty in applying this method clinically [90].

5. Future Outlook

Current treatment with antibiotic cocktails is inadequate for eradicating biofilm infections. It is increasingly evident that biofilm elimination requires the simultaneous degradation of the biofilm matrix and the killing of released bacterial cells. The development of combinatorial therapy of anti-biofilm agents with antibiotics or an anti-biofilm agent-antibiotic conjugate drug will realistically attain an achievable treatment outcome in clinical settings.

388 With rapid advances in compound discovery, it is imperative to identify novel anti-biofilm
389 compounds that can disrupt or disperse biofilms. Natural compounds from plants are excellent
390 sources of potential anti-biofilm compounds, where many QSIs are previously identified [91], while
391 the recently-discovered pyocins and norspermidine displayed promising potential against
392 biofilms [92,93].
393
394 Understanding both active dispersal and disruption will assist in designing better anti-biofilm
395 drugs suited for various clinical purposes. Most importantly, cells released from biofilms by
396 either approach should be contained to prevent the immediate dissemination of pathogens into
397 the circulatory system. Next, the shortcomings of each approach listed previously should be
398 addressed to improve the chances of developing a suitable drug. For instance, it is crucial to re-
399 evaluate the minimal inhibitory concentration (MIC) of accompanying antimicrobial coupled with
400 biofilm dispersal agents, which requires further toxicology and safety studies by
401 pharmacologists and biologists. As for enzymatic-based biofilm disruption, industrial cooperation
402 is necessary to keep manufacturing costs down and develop a practical non-immunogenic
403 formulation.
404
405 Finally, as most studies were conducted either *in vitro* or animal infection models, the newly
406 identified compounds must be evaluated extensively with clinical trials. Future directions should
407 focus on the discovery of novel anti-biofilm agents, with high efficacy against biofilm infections
408 and low toxicity, coupled with the ease of translating to cheap and practical pharmaceuticals.
409
410

411 **References:**

412 1. NIH RESEARCH ON MICROBIAL BIOFILMS. In: Health NIo, ed2002.
413 2. Bjarnsholt T. The role of bacterial biofilms in chronic infections. *APMIS.*
414 2013;121(s136):1-58.
415 3. Mulcahy LR, Isabella VM, Lewis K. *Pseudomonas aeruginosa* Biofilms in Disease.
416 *Microbial Ecology.* 2014;68(1):1-12.
417 4. Micek ST, Wunderink RG, Kollef MH, et al. An international multicenter retrospective
418 study of *Pseudomonas aeruginosa* nosocomial pneumonia: impact of multidrug
419 resistance. *Critical Care.* 2015;19(1):219.
420 5. Fournier A, Voirol P, Krähenbühl M, et al. Antibiotic consumption to detect epidemics of
421 Pseudomonas aeruginosa in a burn centre: A paradigm shift in the epidemiological
422 surveillance of *Pseudomonas aeruginosa* nosocomial infections. *Burns.* 2016;42(3):564-
423 570.
424 6. Høiby N, Bjarnsholt T, Moser C, et al. ESCMID⁎ guideline for the diagnosis and
425 treatment of biofilm infections 2014. *Clinical Microbiology and Infection.* 2015;21:S1-S25.
426 7. Döring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a
427 European consensus. *Journal of Cystic Fibrosis.* 2004;3(2):67-91.
428 8. Goli HR, Nahaei MR, Ahangarzadeh Rezaee M, Hasani A, Samadi Kafil H, Aghazadeh
429 M. Emergence of colistin resistant *Pseudomonas aeruginosa* at Tabriz hospitals, Iran.
430 *Iran J Microbiol.* 2016;8(1):62-69.
431 9. Chávez-Jacobo VM, Hernández-Ramírez KC, Romo-Rodríguez P, et al. CrpP Is a Novel
432 Ciprofloxacin-Modifying Enzyme Encoded by the *Pseudomonas aeruginosa* pUM505
433 Plasmid. *Antimicrobial Agents and Chemotherapy.* 2018;62(6):e02629-02617.
434 10. Schiessl KT, Hu F, Jo J, et al. Phenazine production promotes antibiotic tolerance and
435 metabolic heterogeneity in *Pseudomonas aeruginosa* biofilms. *Nature communications.*
436 2019;10(1):762.
437 11. Flemming H-C, Neu TR, Wozniak DJ. The EPS Matrix: The "House of Biofilm Cells".
438 *Journal of bacteriology.* 2007;189(22):7945-7947.
439 12. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. Spatial Organization and
440 Composition of the Mucosal Flora in Patients with Inflammatory Bowel Disease. *Journal*
441 *of Clinical Microbiology.* 2005;43(7):3380-3389.
442 13. Mah T-F, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. A genetic basis for
443 *Pseudomonas aeruginosa* biofilm antibiotic resistance. *Nature.* 2003;426(6964):306-310.
444 14. Kwan BW, Valenta JA, Benedik MJ, Wood TK. Arrested Protein Synthesis Increases
445 Persister-Like Cell Formation. *Antimicrobial Agents and Chemotherapy.*
446 2013;57(3):1468-1473.
447 15. Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide
448 antibiotic therapy in cystic fibrosis. *Cochrane Database of Systematic Reviews.*
449 2017(10).
450 16. Jones CJ, Wozniak DJ. Psl Produced by Mucoid *Pseudomonas aeruginosa* Contributes
451 to the Establishment of Biofilms and Immune Evasion. *mBio.* 2017;8(3):e00864-00817.
452 17. Skariyachan S, Sridhar VS, Packirisamy S, Kumargowda ST, Challapilli SB. Recent
453 perspectives on the molecular basis of biofilm formation by *Pseudomonas aeruginosa*
454 and approaches for treatment and biofilm dispersal. *Folia Microbiologica.*
455 2018;63(4):413-432.
456 18. Sakuragi Y, Kolter R. Quorum-Sensing Regulation of the Biofilm Matrix Genes (*pel*) of
457 *Pseudomonas aeruginosa*. *Journal of bacteriology.* 2007;189(14):5383-5386.
458 19. Hammer BK, Bassler BL. Quorum sensing controls biofilm formation in *Vibrio cholerae.*
459 *Molecular microbiology.* 2004;51(5):1521-1521.

460 20. Atkinson S, Williams P. Quorum sensing and social networking in the microbial world.
461 *Journal of The Royal Society Interface.* 2009;6(40):959-978.
462 21. Singh PK, Bartalomej S, Hartmann R, et al. *Vibrio cholerae* Combines Individual and
463 Collective Sensing to Trigger Biofilm Dispersal. *Current Biology.* 2017;27(21):3359-
464 3366.e3357.
465 22. Lin Chua S, Liu Y, Li Y, et al. Reduced Intracellular c-di-GMP Content Increases
466 Expression of Quorum Sensing-Regulated Genes in *Pseudomonas aeruginosa*.
467 *Frontiers in cellular and infection microbiology.* 2017;7(451).
468 23. Hengge R. Principles of c-di-GMP signalling in bacteria. *Nat Rev Microbiol.*
469 2009;7(4):263-273.
470 24. Pestrak MJ, Chaney SB, Eggleston HC, et al. *Pseudomonas aeruginosa* rugose small-
471 colony variants evade host clearance, are hyper-inflammatory, and persist in multiple
472 host environments. *PLOS Pathogens.* 2018;14(2):e1006842.
473 25. Povolotsky TL, Hengge R. Genome-Based Comparison of Cyclic Di-GMP Signaling in
474 Pathogenic and Commensal *Escherichia coli* Strains. *Journal of bacteriology.*
475 2016;198(1):111-126.
476 26. Li Y-H, Lau PCY, Tang N, Svensäter G, Ellen RP, Cvitkovitch DG. Novel Two-
477 Component Regulatory System Involved in Biofilm Formation and Acid Resistance in
478 *Streptococcus mutans*. *Journal of bacteriology.* 2002;184(22):6333-6342.
479 27. Zhu X, Rice SA, Barraud N. Nitric Oxide and Iron Signaling Cues Have Opposing Effects
480 on Biofilm Development in *Pseudomonas aeruginosa*. *Applied and Environmental*
481 *Microbiology.* 2019;85(3):e02175-02118.
482 28. Frangipani E, Visaggio D, Heeb S, et al. The Gac/Rsm and cyclic-di-GMP signalling
483 networks coordinately regulate iron uptake in *Pseudomonas aeruginosa*. *Environmental*
484 *Microbiology.* 2014;16(3):676-688.
485 29. Branck TA, Hurley MJ, Prata GN, Crivello CA, Marek PJ. Efficacy of a Sonicating Swab
486 for Removal and Capture of *Listeria monocytogenes* in Biofilms on Stainless Steel.
487 *Applied and Environmental Microbiology.* 2017;83(11):e00109-00117.
488 30. Brinkman CL, Schmidt-Malan SM, Karau MJ, et al. Exposure of Bacterial Biofilms to
489 Electrical Current Leads to Cell Death Mediated in Part by Reactive Oxygen Species.
490 *PLOS ONE.* 2016;11(12):e0168595.
491 31. Paytubi S, de La Cruz M, Tormo JR, et al. A High-Throughput Screening Platform of
492 Microbial Natural Products for the Discovery of Molecules with Antibiofilm Properties
493 against Salmonella. *Frontiers in Microbiology.* 2017;8(326).
494 32. Ding X, Yin B, Qian L, et al. Screening for novel quorum-sensing inhibitors to interfere
495 with the formation of *Pseudomonas aeruginosa* biofilm. *Journal of Medical Microbiology.*
496 2011;60(12):1827-1834.
497 33. DeVito JA, Mills JA, Liu VG, et al. An array of target-specific screening strains for
498 antibacterial discovery. *Nature Biotechnology.* 2002;20(5):478-483.
499 34. Wong Weng R, Oliver Allen G, Linington Roger G. Development of Antibiotic Activity
500 Profile Screening for the Classification and Discovery of Natural Product Antibiotics.
501 *Chemistry & Biology.* 2012;19(11):1483-1495.
502 35. Rajalaxmi M, Beema Shafreen R, Chithiraiselvi K, Karutha Pandian S. An in vitro and in
503 silico identification of antibiofilm small molecules from seawater metaclone SWMC166
504 against *Vibrio cholerae* O1. *Molecular and Cellular Probes.* 2018;39:14-24.
505 36. Yaniv K, Golberg K, Kramarsky-Winter E, et al. Functional marine metagenomic
506 screening for anti-quorum sensing and anti-biofilm activity. *Biofouling.* 2017;33(1):1-13.
507 37. Pandian SK, Subramenium GA. Transcriptomic And Proteomic Analysis To Delineate
508 The Mechanism Of Antibiofilm Activity Of 3-Furancarboxaldehyde On Group A
509 *Streptococcus*. *The FASEB Journal.* 2017;31(1_supplement):658.613-658.613.

510 38. Anderson JK, Huang JY, Wreden C, et al. Chemorepulsion from the Quorum Signal
511 Autoinducer-2 Promotes *Helicobacter pylori* Biofilm Dispersal. *mBio.* 2015;6(4):e00379-
512 00315.
513 39. Lauderdale KJ, Malone CL, Boles BR, Morcuende J, Horswill AR. Biofilm dispersal of
514 community-associated methicillin-resistant *Staphylococcus aureus* on orthopedic implant
515 material. *Journal of Orthopaedic Research.* 2010;28(1):55-61.
516 40. Bhattacharjee A, Nusca TD, Hochbaum AI. Rhamnolipids Mediate an Interspecies
517 Biofilm Dispersal Signaling Pathway. *ACS Chemical Biology.* 2016;11(11):3068-3076.
518 41. Sepehr S, Rahmani-Badi A, Babaie-Naiej H, Soudi MR. Unsaturated Fatty Acid, cis-2-
519 Decenoic Acid, in Combination with Disinfectants or Antibiotics Removes Pre-
520 Established Biofilms Formed by Food-Related Bacteria. *PLOS ONE.* 2014;9(7):e101677.
521 42. Rahmani-Badi A, Sepehr S, Babaie-Naiej H. A combination of cis-2-decenoic acid and
522 chlorhexidine removes dental plaque. *Archives of Oral Biology.* 2015;60(11):1655-1661.
523 43. Wood TL, Gong T, Zhu L, et al. Rhamnolipids from *Pseudomonas aeruginosa* disperse
524 the biofilms of sulfate-reducing bacteria. *npj Biofilms and Microbiomes.* 2018;4(1):22.
525 44. Zezzi do Valle Gomes M, Nitschke M. Evaluation of rhamnolipid and surfactin to reduce
526 the adhesion and remove biofilms of individual and mixed cultures of food pathogenic
527 bacteria. *Food Control.* 2012;25(2):441-447.
528 45. Jensen PØ, Bjarnsholt T, Phipps R, et al. Rapid necrotic killing of polymorphonuclear
529 leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by
530 *Pseudomonas aeruginosa*. *Microbiology.* 2007;153(5):1329-1338.
531 46. Sambanthamoorthy K, Sloup RE, Parashar V, et al. Identification of Small Molecules
532 That Antagonize Diguanylate Cyclase Enzymes To Inhibit Biofilm Formation.
533 *Antimicrobial agents and chemotherapy.* 2012;56(10):5202-5211.
534 47. Kim B, Park J-S, Choi H-Y, Yoon SS, Kim W-G. Terrein is an inhibitor of quorum sensing
535 and c-di-GMP in *Pseudomonas aeruginosa*: a connection between quorum sensing and
536 c-di-GMP. *Scientific Reports.* 2018;8(1):8617.
537 48. Fernicola S, Torquati I, Paiardini A, et al. Synthesis of Triazole-Linked Analogues of c-di-
538 GMP and Their Interactions with Diguanylate Cyclase. *Journal of Medicinal Chemistry.*
539 2015;58(20):8269-8284.
540 49. Chua SL, Liu Y, Yam JK, et al. Dispersed cells represent a distinct stage in the transition
541 from bacterial biofilm to planktonic lifestyles. *Nature communications.* 2014;5:4462.
542 50. Chua SL, Hultqvist LD, Yuan M, et al. In vitro and in vivo generation and characterization
543 of Pseudomonas aeruginosa biofilm-dispersed cells via c-di-GMP manipulation. *Nature*
544 *protocols.* 2015;10(8):1165-1180.
545 51. Barraud N, Storey MV, Moore ZP, Webb JS, Rice SA, Kjelleberg S. Nitric oxide-
546 mediated dispersal in single- and multi-species biofilms of clinically and industrially
547 relevant microorganisms. *Microbial biotechnology.* 2009;2(3):370-378.
548 52. Liu N, Xu Y, Hossain S, et al. Nitric Oxide Regulation of Cyclic di-GMP Synthesis and
549 Hydrolysis in *Shewanella woodyi*. *Biochemistry.* 2012;51(10):2087-2099.
550 53. Li Y, Petrova OE, Su S, et al. BdlA, DipA and Induced Dispersion Contribute to Acute
551 Virulence and Chronic Persistence of *Pseudomonas aeruginosa*. *PLOS Pathogens.*
552 2014;10(6):e1004168.
553 54. Zheng Y, Tsuji G, Opoku-Temeng C, Sintim HO. Inhibition of *P. aeruginosa* c-di-GMP
554 phosphodiesterase RocR and swarming motility by a benzoisothiazolinone derivative.
555 *Chem Sci.* 2016;7(9):6238-6244.
556 55. Barraud N, Hassett DJ, Hwang S-H, Rice SA, Kjelleberg S, Webb JS. Involvement of
557 Nitric Oxide in Biofilm Dispersal of *Pseudomonas aeruginosa*. *Journal of bacteriology.*
558 2006;188(21):7344-7353.
559 56. Collins SA, Kelso MJ, Rineh A, et al. Cephalosporin-3′-Diazeniumdiolate NO Donor
560 Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable

561 *Haemophilus influenzae* Biofilms. *Antimicrobial agents and chemotherapy.*
562 2017;61(2):e02086-02016.
563 57. de la Fuente-Núñez C, Reffuveille F, Fairfull-Smith KE, Hancock REW. Effect of
564 Nitroxides on Swarming Motility and Biofilm Formation, Multicellular Behaviors in
565 *Pseudomonas aeruginosa*. *Antimicrobial agents and chemotherapy.* 2013;57(10):4877-
566 4881.
567 58. Reffuveille F, Fuente-Núñez CdI, Fairfull-Smith KE, Hancock REW. Potentiation of
568 ciprofloxacin action against Gram-negative bacterial biofilms by a nitroxide. *Pathogens*
569 *and Disease.* 2015;73(5).
570 59. Howlin RP, Cathie K, Hall-Stoodley L, et al. Low-Dose Nitric Oxide as Targeted Anti-
571 biofilm Adjunctive Therapy to Treat Chronic *Pseudomonas aeruginosa* Infection in Cystic
572 Fibrosis. *Molecular Therapy.* 2017;25(9):2104-2116.
573 60. Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients. 2015;
574 https://clinicaltrials.gov/ct2/show/NCT02498535. Accessed April 10, 2018.
575 61. Sutherland IW. The biofilm matrix – an immobilized but dynamic microbial environment.
576 *Trends in Microbiology.* 2001;9(5):222-227.
577 62. Ramasubbu N, Thomas LM, Ragunath C, Kaplan JB. Structural Analysis of Dispersin B,
578 a Biofilm-releasing Glycoside Hydrolase from the Periodontopathogen Actinobacillus
579 actinomycetemcomitans. *Journal of Molecular Biology.* 2005;349(3):475-486.
580 63. Yu S, Su T, Wu H, et al. PslG, a self-produced glycosyl hydrolase, triggers biofilm
581 disassembly by disrupting exopolysaccharide matrix. *Cell Res.* 2015;25(12):1352-1367.
582 64. Baker P, Hill PJ, Snarr BD, et al. Exopolysaccharide biosynthetic glycoside hydrolases
583 can be utilized to disrupt and prevent *Pseudomonas aeruginosa* biofilms. *Science*
584 *Advances.* 2016;2(5):e1501632.
585 65. ALKAWASH MA, SOOTHILL JS, SCHILLER NL. Alginate lyase enhances antibiotic
586 killing of mucoid *Pseudomonas aeruginosa* in biofilms. *APMIS.* 2006;114(2):131-138.
587 66. Maiorana A, Bugli F, Papi M, et al. Effect of Alginate Lyase on Biofilm-Grown
588 *Helicobacter pylori* Probed by Atomic Force Microscopy. *International Journal of Polymer*
589 *Science.* 2015;2015:9.
590 67. Fleming D, Chahin L, Rumbaugh K. Glycoside Hydrolases Degrade Polymicrobial
591 Bacterial Biofilms in Wounds. *Antimicrobial agents and chemotherapy.*
592 2017;61(2):e01998-01916.
593 68. Baslé A, Hewitt L, Koh A, et al. Crystal structure of NucB, a biofilm-degrading
594 endonuclease. *Nucleic acids research.* 2017;46(1):473-484.
595 69. Paul K, Rietschel E, Ballmann M, et al. Effect of Treatment with Dornase Alpha on
596 Airway Inflammation in Patients with Cystic Fibrosis. *American Journal of Respiratory*
597 *and Critical Care Medicine.* 2004;169(6):719-725.
598 70. Scala M, Hoy D, Bautista M, Palafoutas JJ, Abubakar K. Pilot study of dornase alfa
599 (Pulmozyme) therapy for acquired ventilator-associated infection in preterm infants.
600 *Pediatric Pulmonology.* 2017;52(6):787-791.
601 71. Baidamshina DR, Trizna EY, Holyavka MG, et al. Targeting microbial biofilms using
602 Ficin, a nonspecific plant protease. *Scientific Reports.* 2017;7:46068.
603 72. Mitrofanova O, Mardanova A, Evtugyn V, Bogomolnaya L, Sharipova M. Effects of
604 Bacillus Serine Proteases on the Bacterial Biofilms. *BioMed Research International.*
605 2017;2017:10.
606 73. Domenech M, García E. N-Acetyl-<span class="sc">l-Cysteine and Cysteamine as New
607 Strategies against Mixed Biofilms of Nonencapsulated *Streptococcus pneumoniae* and
608 Nontypeable <span class="named-content genus-species" id="named-content-
609 2">*Haemophilus influenzae*. *Antimicrobial agents and chemotherapy.*
610 2017;61(2):e01992-01916.

611 74. Kim H-S, Cha E, Kim Y, et al. Raffinose, a plant galactoside, inhibits *Pseudomonas*
612 *aeruginosa* biofilm formation via binding to LecA and decreasing cellular cyclic
613 diguanylate levels. *Scientific Reports.* 2016;6:25318.
614 75. Co JY, Cárcamo-Oyarce G, Billings N, et al. Mucins trigger dispersal of *Pseudomonas*
615 *aeruginosa* biofilms. *npj Biofilms and Microbiomes.* 2018;4(1):23.
616 76. Narayanaswamy VP, Keagy LL, Duris K, et al. Novel Glycopolymer Eradicates
617 Antibiotic- and CCCP-Induced Persister Cells in *Pseudomonas aeruginosa*. *Frontiers in*
618 *Microbiology.* 2018;9(1724).
619 77. Ray VA, Hill PJ, Stover CK, et al. Anti-Psl Targeting of *Pseudomonas aeruginosa*
620 Biofilms for Neutrophil-Mediated Disruption. *Scientific Reports.* 2017;7(1):16065.
621 78. DiGiandomenico A, Keller AE, Gao C, et al. A multifunctional bispecific antibody protects
622 against *Pseudomonas aeruginosa*. *Science Translational Medicine.*
623 2014;6(262):262ra155-262ra155.
624 79. Ali SO, Yu XQ, Robbie GJ, et al. Phase 1 study of MEDI3902, an investigational anti–
625 *Pseudomonas aeruginosa* PcrV and Psl bispecific human monoclonal antibody, in
626 healthy adults. *Clinical Microbiology and Infection.* 2019;25(5):629.e621-629.e626.
627 80. Goodman SD, Obergfell KP, Jurcisek JA, et al. Biofilms can be dispersed by focusing
628 the immune system on a common family of bacterial nucleoid-associated proteins.
629 *Mucosal Immunology.* 2011;4:625.
630 81. Rocco CJ, Davey ME, Bakaletz LO, Goodman SD. Natural antigenic differences in the
631 functionally equivalent extracellular DNABII proteins of bacterial biofilms provide a
632 means for targeted biofilm therapeutics. *Molecular Oral Microbiology.* 2017;32(2):118-
633 130.
634 82. Novotny LA, Jurcisek JA, Ward Jr MO, Jordan ZB, Goodman SD, Bakaletz LO.
635 Antibodies against the majority subunit of type IV pili disperse nontypeable *Haemophilus*
636 *influenzae* biofilms in a LuxS-dependent manner and confer therapeutic resolution of
637 experimental otitis media. *Molecular microbiology.* 2015;96(2):276-292.
638 83. Gusarov I, Shatalin K, Starodubtseva M, Nudler E. Endogenous Nitric Oxide Protects
639 Bacteria Against a Wide Spectrum of Antibiotics. *Science.* 2009;325(5946):1380-1384.
640 84. Guilhen C, Charbonnel N, Parisot N, et al. Transcriptional profiling of *Klebsiella*
641 *pneumoniae* defines signatures for planktonic, sessile and biofilm-dispersed cells. *BMC*
642 *genomics.* 2016;17:237.
643 85. Uppuluri P, Acosta Zaldívar M, Anderson MZ, et al. *Candida albicans* Dispersed Cells
644 Are Developmentally Distinct from Biofilm and Planktonic Cells. *mBio.*
645 2018;9(4):e01338-01318.
646 86. Chambers JR, Cherny KE, Sauer K. Susceptibility of *Pseudomonas aeruginosa*
647 Dispersed Cells to Antimicrobial Agents Is Dependent on the Dispersion Cue and Class
648 of the Antimicrobial Agent Used. *Antimicrobial agents and chemotherapy.*
649 2017;61(12):e00846-00817.
650 87. Chua SL, Tan SY, Rybtke MT, et al. Bis-(3'-5')-cyclic dimeric GMP regulates
651 antimicrobial peptide resistance in *Pseudomonas aeruginosa*. *Antimicrobial agents and*
652 *chemotherapy.* 2013;57(5):2066-2075.
653 88. Cherny KE, Sauer K. *Pseudomonas aeruginosa* requires the DNA-specific
654 endonuclease EndA to degrade eDNA to disperse from the biofilm. *Journal of*
655 *bacteriology.* 2019:JB.00059-00019.
656 89. Fleming D, Rumbaugh K. The Consequences of Biofilm Dispersal on the Host. *Scientific*
657 *Reports.* 2018;8(1):10738.
658 90. Pleszczyńska M, Wiater A, Janczarek M, Szczodrak J. (1→3)-α-d-Glucan hydrolases in
659 dental biofilm prevention and control: A review. *International Journal of Biological*
660 *Macromolecules.* 2015;79:761-778.

661 91. Lu L, Hu W, Tian Z, et al. Developing natural products as potential anti-biofilm agents.
662 *Chinese Medicine.* 2019;14(1):11.
663 92. Oluyombo O, Penfold CN, Diggle SP. Competition in Biofilms between Cystic Fibrosis
664 Isolates of *Pseudomonas aeruginosa* Is Shaped by R-Pyocins. *mBio.*
665 2019;10(1):e01828-01818.
666 93. Qu L, She P, Wang Y, et al. Effects of norspermidine on *Pseudomonas aeruginosa*
667 biofilm formation and eradication. *MicrobiologyOpen.* 2016;5(3):402-412.

668

Author biosketch:

Dr. Song Lin Chua is currently an Assistant Professor in the Hong Kong Polytechnic University, Hong Kong SAR China, and Principal Investigator in the State Key Laboratory of Chemical Biology and Drug Discovery. After graduating with a Ph.D. from the National University of Singapore, he was later awarded the prestigious Lee Kong Chian Medicine Fellowship to work as Principal Investigator in the School of Medicine jointly operated by Nanyang Technological University and Imperial College London. His research interests involve the elucidation of mechanisms in biofilm dispersal and the development of anti-biofilm agents to eradicate biofilm infections. He has published in more than 20 publications and book reviews, with significant contributions in Nature Communications, Nature Protocols, and Cell Research.

681 **Table 1:** General comparison between active biofilm dispersal and biofilm disruption.

	Biofilm Active Dispersal	Biofilm Disruption
Treatment	Use of chemical stimulus which signals bacterial cells to terminate their biofilm lifestyle and exit the EPS via the self-production of matrix-degrading enzymes and expression of motility apparatus (flagella or pili).	Direct targeting or degradation of the biofilm matrix, leading to the catastrophic collapse of biofilm structure and ejection of embedded cells
Penetrability into biofilms	Dispersal agents need to diffuse into EPS and enter biofilm cells.	Biofilm disruptors can demolish biofilms from the outside quickly, bypassing the need to pass through biofilm matrix and microbial cell walls.
Types of agents	Mostly chemicals which act as stress to stimulate biofilm dispersal	Mostly enzymes which catalyzed the degradation of EPS
Physiology of released cells	Dispersed cells have unique physiology from biofilm and planktonic cells [49]	Disrupted cells have similar physiology with biofilm cells [63]
Antimicrobial resistance of released cells	Dispersed cells may have altered resistance/sensitivity to antibiotic classes [87]	Disrupted cells have similar resistance/similarity to antibiotic classes as biofilms [63]
Virulence of released cells	Dispersed cells have higher production of virulence factors than biofilm and planktonic cells [49]	Disrupted cells have similar virulence as biofilm cells [63]

682

683 **Figure legends:**



684

685 **Figure 1:** Typical biofilm life cycle in bacteria. (A) The planktonic cells first attach onto a
686 surface. (B) Bacterial cells lose their motility and start to produce EPS for biofilm formation. (C)
687 Biofilm matures and thickens where antibiotics and immune cells are unable to penetrate
688 efficiently into the biofilm. (D) As biofilm ages, the cells disperse from the biofilms and enter a
689 different transient dispersal phase. After a while, the dispersed cells reverted to planktonic cells,
690 where the life cycle restarts.

691



692

693 **Figure 2:** Role of c-di-GMP signaling in the biofilm life cycle and the potential targets against it.
694 An increase in c-di-GMP levels by DGCs, in general, leads to biofilm formation, while reduction
695 by PDEs induces biofilm dispersal. Strategies developed against biofilms include inhibition of
696 bacterial attachment to surfaces and biofilm formation, active dispersal of biofilms, and
697 disruption of the biofilm matrix.
698



699

700 **Figure 3:** Comparison of biofilm dispersal and disruption. (A) Biofilm dispersal. The dispersal
701 agent acts as a stimulus to drive biofilm cells into dispersal, leading to considerable changes in
702 physiology to dispersed cell state. (B) Biofilm disruption. The biofilm disrupting agent directly
703 degrades the biofilm matrix to eject biofilm cells with little changes to their physiological state.
704

705



706 **Figure 4:** Development of various anti-biofilm strategies. (A) Biofilm dispersal strategies include
707 using QS molecules as chemorepellants, DGC inhibitors (c-di-GMP analogs), and PDE
708 activators (such as NO). (B) Biofilm disruption strategies include enzymatic degradation of EPS
709 by glycosyl hydrolase, protease and DNase; non-enzymatic degradation of EPS components by
710 N-acetyl cysteine; and antibody targeting of EPS.

711